Biologics License Application
Entity.
- Evidence
- 33 documents Β· 12 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 4 Sept 2026, last seen 6 Oct 2026
- Measured
- 46% of mentions say something specific about it; the rest only name it
- As of
- 7 Oct 2026
Where this comes from
- Clinical Trials Arena Β· 2026-10-06 Β· Vaxcyteβs stock up after pneumococcal vaccine proves non-inferiority (opens the source in a new tab)
- The Clinical Trial Vanguard Β· 2026-10-06 Β· Novoβs Denecimig Got a Green Light From Clinicians and a Red Light From an Inspector: Who Failed? (opens the source in a new tab)
- AllSci News Β· 2026-10-05 Β· US FDA delays review of Novo hemophilia drug denecimig over manufacturing issue (opens the source in a new tab)
- The Clinical Trial Vanguard Β· 2026-10-03 Β· FDA extends denecimig review timeline, no decision date set (opens the source in a new tab)
- AllSci News Β· 2026-10-02 Β· Pierre Fabre, Atara resubmit Ebvallo BLA after two FDA CRLs (opens the source in a new tab)
- AllSci News Β· 2026-10-02 Β· AstraZeneca, Daiichi team with Summit to pair Datroway with ivonescimab in Phase III TNBC push (opens the source in a new tab)
- AllSci News Β· 2026-10-01 Β· Lillyβs retatrutide delivers 20.8% weight loss in Phase III diabetes-obesity trial (opens the source in a new tab)
- Clinical Trials Arena Β· 2026-10-01 Β· Invivydβs Covid-directed mAb hits Phase III safety goals (opens the source in a new tab)
- European Medical Journal Β· 2026-09-30 Β· Triple-Action Weight-Loss Drug Shows Promise for Heart Health (opens the source in a new tab)
- Clinical Trials Arena Β· 2026-09-30 Β· Mirum charts positive course for hepatitis delta drug on first Phase III win (opens the source in a new tab)
- AllSci News Β· 2026-09-30 Β· Kodiakβs Zenkuda and tabirafusp-ted meet Phase III endpoints in wet AMD (opens the source in a new tab)